Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients

被引：1
|
作者：
Alacacioglu, A. [1 ]
Kebapcilar, L. [2 ]
Pamuk, B. Onder [2 ]
Sop, G. [2 ]
Kucukiravul, C. [2 ]
Bozkaya, G. [3 ]
Yuksel, A. [2 ]
Alacacioglu, I. [4 ]
Sari, I. [2 ]
机构：
[1] Bozyaka Res & Training Hosp, Dept Med Oncol, TR-35360 Izmir, Turkey
[2] Bozyaka Res & Training Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Bozyaka Res & Training Hosp, Dept Biochem, TR-35360 Izmir, Turkey
[4] Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey
来源：
JOURNAL OF BUON | 2013年 / 18卷 / 03期
关键词：
anthracycline; breast cancer; SOD; TBARS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery. Methods: Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracydine-based chemotherapy. Results: Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5 +/- 0.6 vs 5.9 +/- 0.9}anon; p=0.038) and a significant reduction to baseline values in SOD levels (226.5 +/- 61.0 vs 203.1 +/- 48.3 U/mL; p=0.037) in patients following 6 cycles of adjuvant chemotherapy. Conclusion: The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
引用
收藏
页码：614 / 618
页数：5
相关论文
共 50 条
  • [21] Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Szkandera, Joanna
    Absenger, Gudrun
    Dandachi, Nadia
    Regitnig, Peter
    Lax, Sigurd
    Stotz, Michael
    Samonigg, Hellmut
    Renner, Wilfried
    Gerger, Armin
    MOLECULAR GENETICS AND GENOMICS, 2012, 287 (09) : 755 - 764
  • [22] Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Joanna Szkandera
    Gudrun Absenger
    Nadia Dandachi
    Peter Regitnig
    Sigurd Lax
    Michael Stotz
    Hellmut Samonigg
    Wilfried Renner
    Armin Gerger
    Molecular Genetics and Genomics, 2012, 287 : 755 - 764
  • [23] Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    François Bertucci
    Nathalie Borie
    Henri Roche
    Thomas Bachelot
    Jean-Marc Le Doussal
    Gaëtan Macgrogan
    Stéphane Debono
    Agnès Martinec
    Isabelle Treilleux
    Pascal Finetti
    Benjamin Esterni
    Jean-Marc Extra
    Jean Geneve
    Fabienne Hermitte
    Christian Chabannon
    Jocelyne Jacquemier
    Anne-Laure Martin
    Michel Longy
    Dominique Maraninchi
    Vincent Fert
    Daniel Birnbaum
    Patrice Viens
    Breast Cancer Research and Treatment, 2011, 127 : 363 - 373
  • [24] Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Bertucci, Francois
    Borie, Nathalie
    Roche, Henri
    Bachelot, Thomas
    Le Doussal, Jean-Marc
    Macgrogan, Gaetan
    Debono, Stephane
    Martinec, Agnes
    Treilleux, Isabelle
    Finetti, Pascal
    Esterni, Benjamin
    Extra, Jean-Marc
    Geneve, Jean
    Hermitte, Fabienne
    Chabannon, Christian
    Jacquemier, Jocelyne
    Martin, Anne-Laure
    Longy, Michel
    Maraninchi, Dominique
    Fert, Vincent
    Birnbaum, Daniel
    Viens, Patrice
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (02) : 363 - 373
  • [25] Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors
    Rouzier, R
    Mathieu, MC
    Sideris, L
    Youmsi, E
    Rajan, R
    Garbay, JR
    André, F
    Marsiglia, H
    Spielmann, M
    Delaloge, S
    CANCER, 2004, 101 (05) : 918 - 925
  • [26] Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors
    Serrano, Jose M.
    Mata, Rebeca
    Gonzalez, Iria
    Del Castillo, Silvia
    Muniz, Javier
    Morales, Luis J.
    Espinosa, Maria Jesus
    Moreno, Fernando
    Jimenez, Rosa
    Cristobal, Carmen
    Graupner, Catherine
    Talavera, Pedro
    Landaluce, Carlos Gutierez
    Curcio, Alejandro
    Alonso, Javier
    Guerra, Juan A.
    Alonso, Joaquin J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 382 : 52 - 59
  • [27] Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
    Zhao, Ying-Chun
    Wang, Yan
    Ni, Xiao-Jian
    Li, Yong
    Wang, Xiu-Ming
    Zhu, Yong-Yun
    Luo, Chuan-Yu
    MOLECULAR MEDICINE REPORTS, 2014, 9 (02) : 614 - 620
  • [28] Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer
    Chavez-MacGregor, Mariana
    Brown, Erika
    Lei, Xiudong
    Litton, Jennifer
    Meric-Bernstram, Funda
    Mettendorf, Elizabeth
    Hernandez, Leonel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana Maria
    CANCER, 2012, 118 (02) : 326 - 332
  • [29] The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
    Nolan, Luke
    Darby, Angela
    Boleti, Katia
    Simmonds, Peter
    BREAST, 2011, 20 (02) : 151 - 154
  • [30] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
    Xing, Mingyou
    Wang, Jun
    Yang, Qin
    Wang, Yu
    Li, Jiansha
    Xiong, Jing
    Zhou, Sheng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 861 - 872
12345